We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Organon & Co. (OGN - Free Report) reported second-quarter 2021 adjusted earnings of $1.72 per share, which beat the Zacks Consensus Estimate of $1.49 per share. The company reported earnings of $2.52 per share in the year-ago quarter.
Total revenues in the second quarter were $1.60 billion, up from $1.53 billion in the year-ago quarter. Total revenues in the second quarter increased 5% year over year on a reported basis. Sales also beat the Zacks Consensus Estimate of $1.54 billion.
Shares of Organon were up in pre-market trading.
Along with earnings release, Organon declared its inaugural quarterly dividend of $0.28 per share of its issued and outstanding common stock.
All growth rates mentioned below are on a year-over-year and reported basis.
Quarter in Detail
The company records revenues under its three business franchisees, namely – Women’s Health, Biosimilars and Established Brands.
In the reported quarter, Women’s Health sales were $417 million, up 19% from the year-ago quarter, driven by strong growth in Nexplanon, a single-rod subdermal contraceptive implant. Growth in fertility also contributed to Women’s Health revenues in the quarter. Sales of Follistim, AQ Cartridge (follitropin beta injection) were positively impacted by a combination of COVID-19 recovery and increased demand during the quarter.
Biosimilars revenues were $86 million, up 43% from the year-ago quarter, driven by continued demand growth for Renflexis (infliximab-abda) and strong uptake of Ontruzant (trastuzumab-dttb) in the United States. This was partially offset by a decrease in sales in the EU, due to increasing competitive pressures.
Biosimilars revenues were $1.04 billion, down 4% from the year-ago quarter, owing to the loss of exclusivity of Zetia (ezetimibe) in Japan. Established Brands represents a broad portfolio of medicines, which generally are beyond market exclusivity, like leading brands in cardiovascular, respiratory, dermatology and non-opioid pain management, for which generic competition varies from market to market.
Research and development costs were $76 million, up 49% on a yearly basis, while selling, general and administrative expenses rose 46.5% year over year to $416 million.
We remind investors that, in June 2021, pharma giant Merck (MRK - Free Report) completed the spinoff of its Women’s Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon.
2021 Guidance
Organon reaffirmed the financial guidance it provided earlier this year. The company expects revenues in the range of $6.1-$6.4 billion for 2021, unchanged from the previous projection.
Adjusted EBITDA margin is expected in the range of 36%-38%, while non-GAAP tax rate is projected between 17.5%-19.5%, both unchanged from the previous expectation.
Image: Bigstock
Organon's (OGN) Q2 Earnings & Revenues Surpass Estimates
Organon & Co. (OGN - Free Report) reported second-quarter 2021 adjusted earnings of $1.72 per share, which beat the Zacks Consensus Estimate of $1.49 per share. The company reported earnings of $2.52 per share in the year-ago quarter.
Total revenues in the second quarter were $1.60 billion, up from $1.53 billion in the year-ago quarter. Total revenues in the second quarter increased 5% year over year on a reported basis. Sales also beat the Zacks Consensus Estimate of $1.54 billion.
Shares of Organon were up in pre-market trading.
Along with earnings release, Organon declared its inaugural quarterly dividend of $0.28 per share of its issued and outstanding common stock.
All growth rates mentioned below are on a year-over-year and reported basis.
Quarter in Detail
The company records revenues under its three business franchisees, namely – Women’s Health, Biosimilars and Established Brands.
In the reported quarter, Women’s Health sales were $417 million, up 19% from the year-ago quarter, driven by strong growth in Nexplanon, a single-rod subdermal contraceptive implant. Growth in fertility also contributed to Women’s Health revenues in the quarter. Sales of Follistim, AQ Cartridge (follitropin beta injection) were positively impacted by a combination of COVID-19 recovery and increased demand during the quarter.
Biosimilars revenues were $86 million, up 43% from the year-ago quarter, driven by continued demand growth for Renflexis (infliximab-abda) and strong uptake of Ontruzant (trastuzumab-dttb) in the United States. This was partially offset by a decrease in sales in the EU, due to increasing competitive pressures.
Biosimilars revenues were $1.04 billion, down 4% from the year-ago quarter, owing to the loss of exclusivity of Zetia (ezetimibe) in Japan. Established Brands represents a broad portfolio of medicines, which generally are beyond market exclusivity, like leading brands in cardiovascular, respiratory, dermatology and non-opioid pain management, for which generic competition varies from market to market.
Research and development costs were $76 million, up 49% on a yearly basis, while selling, general and administrative expenses rose 46.5% year over year to $416 million.
We remind investors that, in June 2021, pharma giant Merck (MRK - Free Report) completed the spinoff of its Women’s Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon.
2021 Guidance
Organon reaffirmed the financial guidance it provided earlier this year. The company expects revenues in the range of $6.1-$6.4 billion for 2021, unchanged from the previous projection.
Adjusted EBITDA margin is expected in the range of 36%-38%, while non-GAAP tax rate is projected between 17.5%-19.5%, both unchanged from the previous expectation.
Zacks Rank & Stocks to Consider
Organon currently carries a Zacks Rank #3 (Hold). Top-ranked stocks in the healthcare sector include Catalent, Inc. (CTLT - Free Report) and Vertex Pharmaceuticals Incorporated (VRTX - Free Report) , both carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Catalent’s earnings estimates have been revised 0.7% upward for 2021 and 2.6% for 2022 over the past 60 days. The stock has surged 13.5% year to date.
Vertex earnings estimates have been revised 9.4% upward for 2021 and 5.5% for 2022 over the past 60 days.